Aggregate Spend and Transparency Reporting in Clinical Trials

Physician payment disclosures such as the Sunshine Act impact all stakeholders involved in clinical research, including sponsors, investigators, sites and third parties (CROs, SMOs). Pharmaceutical, biotechnology, and medical device companies are now held accountable for tracking and reporting clinical trial research payments made to physicians.

CHI's Inaugural Aggregate Spend and Transparency Reporting in Clinical Trials: Sunshine Act Compliance from a Clinical Ops Perspective helps navigate these new reporting requirements by outlining the impact of the Sunshine Act and other global laws on clinical research, how to build successful working relationships with key stakeholders responsible for reporting, best practices in spend reporting from a clinical ops perspective, and how to analyze aggregate spend data to improve business and clinical trial management.